Pacor M L, Di Lorenzo G, Martinelli N, Mansueto P, Rini G B, Corrocher R
Dipartimento di Medicina Clinica e Sperimentale, Sezione di Medicina Interna, Università degli Studi di Verona, Italy.
Clin Exp Allergy. 2004 Apr;34(4):639-45. doi: 10.1111/j.1365-2222.2004.1907.x.
Atopic dermatitis (AD) is a chronic allergic inflammatory disease, which manifests itself with eczematous skin lesions.
We compared the clinical efficacy of tacrolimus ointment (0.1%) given twice a day and oral cyclosporine (3 mg/kg) given once daily. Rescue medication for itching included cetirizine 10-20 mg (equal to one or two tables).
Thirty patients, aged 13-45 years (mean+/-SD 27.1+/-10.9), with a history of moderate-to-severe AD were randomized to treatments, 15 patients for each treatments. Assessment of efficacy was based on SCORAD, on scores of daily itching, erythema, interference with sleep, due to the skin condition and days without use of cetirizine tablets. SCORAD, measured on a scale (0-103), was evaluated before treatment (0) and at 7, 14, 21, 28, 35 and 42 days after treatment. Similarly, the means of daily symptoms, on a scale (0-3), were evaluated before the treatment (0) and at 7, 14, 21, 28, 35 and 42 days after treatment; finally, on day without use of cetirizine tablets. The safety of the study treatments was assessed through haematologic, biochemical and urinary testing and on systolic and diastolic blood pressures and heart rate measurements.
SCORAD decreased in the two treatment groups 14 days after the beginning of the period study. However, the patients in tacrolimus ointment group reported significantly lower SCORAD than those treated with oral cyclosporine. Overall SCORAD, as assessed by the area under the curve (AUC) day(0-42) (score/day), was significantly lower in the tacrolimus ointment group when compared with oral cyclosporine (P<0.001). Similarly, AUC day(0-42) (score/day) for itching, erythema and number of nights without interference with the sleep due to skin condition were significantly lower in the group of patients treated with tacrolimus compared with those treated with cyclosporine (P=0.003, 0.005 and 0.01, respectively). As regards the use of rescue medication, expressed by median of number of days without use of anti-H(1), it was significantly lower in the group treated with tacrolimus (82.5) than in the cyclosporine group (76.5) (P=0.03). There were no appreciable changes in haematological and biochemical indices, in both treatments groups.
The results of this comparative study demonstrate that tacrolimus ointment twice daily and cyclosporine administered orally once daily are effective on SCORAD, daily symptoms and anti-H(1) rescue. When we compared tacrolimus and cyclosporine there was a faster onset of action in the group treated with tacrolimus. The two drugs presented the same safety. However, these data support the preferential use of topical tacrolimus 0.1% in AD, because cyclosporine has potential side-effects.
特应性皮炎(AD)是一种慢性过敏性炎症性疾病,表现为湿疹样皮肤损害。
我们比较了每天两次外用0.1%他克莫司软膏与每天一次口服环孢素(3mg/kg)的临床疗效。止痒的急救药物包括10 - 20mg西替利嗪(相当于一或两片)。
30例年龄在13 - 45岁(平均±标准差27.1±10.9)、有中度至重度AD病史的患者被随机分配接受治疗,每种治疗15例。疗效评估基于SCORAD、每日瘙痒、红斑、因皮肤状况导致的睡眠干扰评分以及不使用西替利嗪片的天数。SCORAD采用0 - 103分制,在治疗前(0天)以及治疗后7、14、21、28、35和42天进行评估。同样,每日症状评分采用0 - 3分制,在治疗前(0天)以及治疗后7、14、21、28、35和42天进行评估;最后评估不使用西替利嗪片的天数。通过血液学、生化和尿液检测以及收缩压、舒张压和心率测量来评估研究治疗的安全性。
在研究期开始14天后,两个治疗组的SCORAD均下降。然而,他克莫司软膏组患者的SCORAD显著低于口服环孢素治疗组。通过曲线下面积(AUC)日(0 - 42)(评分/天)评估的总体SCORAD,他克莫司软膏组显著低于口服环孢素组(P<0.001)。同样,与环孢素治疗组相比,他克莫司治疗组患者的瘙痒、红斑以及因皮肤状况导致无睡眠干扰的夜晚数的AUC日(0 - 42)(评分/天)显著更低(分别为P = 0.003、0.005和0.01)。至于急救药物的使用,以不使用抗H(1)药物的天数中位数表示,他克莫司治疗组(82.5天)显著低于环孢素组(76.5天)(P = 0.03)。两个治疗组的血液学和生化指标均无明显变化。
这项比较研究的结果表明,每天两次外用他克莫司软膏和每天一次口服环孢素对SCORAD、每日症状和抗H(1)急救均有效。当我们比较他克莫司和环孢素时,他克莫司治疗组起效更快。两种药物安全性相同。然而,这些数据支持在AD中优先使用0.1%的外用他克莫司,因为环孢素有潜在副作用。